Peptide record

TPDB92526

iRGD Anticancer Blood-Brain Barrier Cell-penetrating Peptides Tumor-homing Peptides modified_plain modified
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92526
iRGD
Anticancer Blood-Brain Barrier Cell-penetrating Peptides Tumor-homing Peptides
Cancer-related peptides Delivery and barrier-penetrating peptides
Peptipedia BBPpredict CPPsite3.0 MLCPP 2.0 StackTHP StackTHPred TumorHoPe2.0
modified_plain
Yes
A 9-aa modified multi-activity (Anticancer, Blood-Brain Barrier, Cell-penetrating Peptides, and other sources) peptide sequence curated from Peptipedia, BBPpredict, CPPsite3.0, and other sources, with an available 3D structural model.
C-terminal: Conjugated with FITC
Sequence
CRGDKGPDC
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
9 reviewed residue count
Conjugated with FITC Activity
L Activity
Linear Activity
Free Activity
N[C@@H](Cc1ccccc1)C(=O)/N=C/C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O Activity
Evidence Records 1 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

4T1, B16, MDA-MB-231, And Skbr3 Cell Lines

Assay & Model

Four-week-old BALB/c female mice
Four-week-old BALB/c female mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
m(KLA) peptide via GG bridge
Cytoplasm
FITC-m(KLA)-iRGD showed rapid cellular uptake at 1 h. In MDA-MB-231 and 4T1 cells, the amount of internalized FITC-m(KLA)-iRGD peaked at approximately 2 h and not in normal cells.
Endocytosis
In vitro and in vivo
CCTTSSCCCCC
Additional Detail Fields 1 fields
CCTTSSCCCCC